Ardelyx Presents Real-World Data at ACG 2026 Showing Reduced Healthcare Resource Utilization Following IBSRELA® Initiation in Adults with IBS-C
Ardelyx presented real-world data at ACG 2026 showing GI-related healthcare resource utilization fell significantly after adults with IBS-C started IBSRELA (tenapanor). In a retrospective analysis of 470 patients at a national gastroenterology practice, median GI-related visits dropped from 4.5 in the year before initiation to 3.0 in the year after (P<0.001), with consistent reductions across subgroups.
Key figures
- Drug Name
- IBSRELA (tenapanor)
- Phase Of Trial
- Phase 3
- P value
- P<0.001
- Study patients
- 470
- Hru visits after
- 3
- Hru visits before
- 4.5
- Ibs c us patients
- 12 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.